Literature DB >> 8654444

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

A Sánchez-Quijano1, J Andreu, F Gavilán, F Luque, M A Abad, B Soto, J Muñoz, J M Aznar, M Leal, E Lissen.   

Abstract

The aim of the present study was to investigate the possible role of human immunodeficiency virus (HIV) infection in the natural course of chronic hepatitis C. Seventy-six adult patients with chronic parenterally acquired hepatitis C virus (HCV) infection examined from 1989 to 1993 were enrolled; of these 32 (42.1%) were HIV positive and 44 (57.9%) were HIV negative. Serum HCV RNA quantitation was carried out by polymerase chain reaction in a well-characterized group (n = 20; 11 HIV positive and 9 HIV negative). Distribution of histological findings in liver biopsies from both HIV-infected and noninfected patients was similar. However, within 15 years after initial HCV infection, 8 of 32 (25%) HIV-positive patients developed cirrhosis, in comparison with only 2 of 31 (6.5%) patients in the HIV-negative group (p < 0.05); similar incidences of cirrhosis were found in both patient groups within 5 and 10 years after HCV infection. Most of the HIV-negative cirrhotic patients (9 of 11) developed cirrhosis in a time interval longer than 15 years. Finally, HCV load was almost ten times higher (1 10-fold dilution) in the HIV-positive group, but this difference did not reach statistical significance in this small study population. These results suggest that HIV infection can alter the natural course of chronic parenterally acquired hepatitis C, causing an unusually rapid progression to cirrhosis.

Entities:  

Mesh:

Year:  1995        PMID: 8654444     DOI: 10.1007/bf01691375

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

Review 1.  Non-A, Non-B hepatitis: sorting through a diagnosis of exclusion.

Authors:  M J Alter
Journal:  Ann Intern Med       Date:  1989-04-15       Impact factor: 25.391

2.  [Hepatitis in drug addicts].

Authors:  M Bruguera
Journal:  Med Clin (Barc)       Date:  1984-01-14       Impact factor: 1.725

3.  Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease.

Authors:  N Kato; O Yokosuka; K Hosoda; Y Ito; M Ohto; M Omata
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

4.  Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study.

Authors:  M E Eyster; M W Fried; A M Di Bisceglie; J J Goedert
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

5.  Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease.

Authors:  H Hagiwara; N Hayashi; E Mita; M Naito; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1993-04       Impact factor: 17.425

6.  Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux.

Authors:  N Boyer; P Marcellin; C Degott; F Degos; A G Saimot; S Erlinger; J P Benhamou
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

7.  Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users.

Authors:  P Simmonds; L Q Zhang; H G Watson; S Rebus; E D Ferguson; P Balfe; G H Leadbetter; P L Yap; J F Peutherer; C A Ludlam
Journal:  Lancet       Date:  1990-12-15       Impact factor: 79.321

8.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

9.  The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use.

Authors:  S C Gordon; R S Elloway; J C Long; C F Dmuchowski
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

10.  Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.

Authors:  K Bjøro; S S Frøland; Z Yun; H H Samdal; T Haaland
Journal:  N Engl J Med       Date:  1994-12-15       Impact factor: 91.245

View more
  23 in total

Review 1.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 2.  The HCV and HIV coinfected patient: what have we learned about pathophysiology?

Authors:  Andrew H Talal; P Wilfredo Canchis; Ira Jacobson
Journal:  Curr Gastroenterol Rep       Date:  2002-02

3.  [Not Available].

Authors:  Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

4.  Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

Authors:  V Soriano; J García-Samaniego; E Valencia; R Rodríguez-Rosado; F Muñoz; J González-Lahoz
Journal:  Eur J Epidemiol       Date:  1999-01       Impact factor: 8.082

5.  An interrupted time series evaluation of a hepatitis C intervention for persons with HIV.

Authors:  Rae Jean Proeschold-Bell; Bettina Hoeppner; Baishakhi Taylor; Sarah Cohen; Rachel Blouin; Beth Stringfield; Andrew J Muir
Journal:  AIDS Behav       Date:  2011-11

6.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Authors:  Mark Hull; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Giguère; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

7.  Hepatitis C virus core protein enhances HIV-1 replication in human macrophages through TLR2, JNK, and MEK1/2-dependent upregulation of TNF-α and IL-6.

Authors:  Gokul Swaminathan; Daniel Pascual; Germaine Rival; Renzo Perales-Linares; Julio Martin-Garcia; Sonia Navas-Martin
Journal:  FEBS Lett       Date:  2014-08-14       Impact factor: 4.124

8.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 9.  Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations.

Authors:  Miriam Romero; Mayte Pérez-Olmeda; Javier García-Samaniego; Vicente Soriano
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.

Authors:  Erica E M Moodie; Nitika Pant Pai; Marina B Klein
Journal:  PLoS One       Date:  2009-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.